The finding of significantly less CD8+ and CD4+ T cells in the spleens explanted from mice in the PD-1 monotherapy group supports the conclusion that PD-1 monotherapy was not beneficial for the anti-cancer immune response, and may in fact have been detrimental. This evidence concerns the gene PDCD1 and cancer.